Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease

  • Kumarasinghe, L.
  • Ramirez, J.
  • Mayor, U.
  • Zugaza, J.L.
  • Sanz, P.
  • García-Gimeno, María Adelaida|||0000-0002-6483-3912
[EN] Laforin and Malin are two proteins that are encoded by the genes EPM2A and EPM2B, respectively. Laforin is a glucan phosphatase and Malin is an E3-ubiquitin ligase, and these two proteins function as a complex. Mutations occurring at the level of one of the two genes lead to the accumulation of an aberrant form of glycogen meant to cluster in polyglucosans that go under the name of Lafora bodies. Individuals affected by the appearance of these polyglucosans, especially at the cerebral level, experience progressive neurodegeneration and several episodes of epilepsy leading to the manifestation of a fatal form of a rare disease called Lafora disease (LD), for which, to date, no treatment is available. Despite the different dysfunctions described for this disease, many molecular aspects still demand elucidation. An effective way to unknot some of the nodes that prevent the achievement of better knowledge of LD is to focus on the substrates that are ubiquitinated by the E3-ubiquitin ligase Malin. Some substrates have already been provided by previous studies based on protein-protein interaction techniques and have been associated with some alterations that mark the disease. In this work, we have used an unbiased alternative approach based on the activity of Malin as an E3-ubiquitin ligase. We report the discovery of novel bonafide substrates of Malin and have characterized one of them more deeply, namely PIP3-dependent Rac exchanger 1 (P-Rex1). The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origin of the accumulation of the polyglucosans present in the disease., This work has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), and a grant from la Fundacio La Marato TV3 (202032), to PS; and a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00 to PS and MGG.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

TRIM32 and Malin in Neurological and Neuromuscular Rare Diseases

  • Kumarasinghe, Lorena
  • Xiong, Lu
  • García-Gimeno, María Adelaida
  • Lazzari, Elisa
  • Sanz, Pascual
  • Meroni, Germana
21 páginas, 7 figuras. Some elements used in the figures were adapted from Servier Medical Art (https://smart.servier.com/) (accessed on 12 February 2021)., licensed under a Creative Commons Attribution 3.0 Generic License. Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cells10040820/s1, Table S1: Reported TRIM32 substrates/interactors listed alphabetically. Table S2: Reported malin substrates/interactors listed alphabetically, Tripartite motif (TRIM) proteins are RING E3 ubiquitin ligases defined by a shared domain structure. Several of them are implicated in rare genetic diseases, and mutations in TRIM32 and TRIM-like malin are associated with Limb-Girdle Muscular Dystrophy R8 and Lafora disease, respectively. These two proteins are evolutionary related, share a common ancestor, and both display NHL repeats at their C-terminus. Here, we revmniew the function of these two related E3 ubiquitin ligases discussing their intrinsic and possible common pathophysiological pathways., This work has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), to P.S. E.L. is supported by a post-doctoral grant issued by Fondazione Umberto Veronesi., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease

  • Kumarasinghe, Lorena
  • García-Gimeno, María Adelaida
  • Ramírez, J.
  • Mayor, U.
  • Zugaza, J. L.
  • Sanz, Pascual
14 páginas, 7 figuras, 1 tabla., Laforin and Malin are two proteins that are encoded by the genes EPM2A and EPM2B, respectively. Laforin is a glucan phosphatase and Malin is an E3-ubiquitin ligase, and these two proteins function as a complex. Mutations occurring at the level of one of the two genes lead to the accumulation of an aberrant form of glycogen meant to cluster in polyglucosans that go under the name of Lafora bodies. Individuals affected by the appearance of these polyglucosans, especially at the cerebral level, experience progressive neurodegeneration and several episodes of epilepsy leading to the manifestation of a fatal form of a rare disease called Lafora disease (LD), for which, to date, no treatment is available. Despite the different dysfunctions described for this disease, many molecular aspects still demand elucidation. An effective way to unknot some of the nodes that prevent the achievement of better knowledge of LD is to focus on the substrates that are ubiquitinated by the E3-ubiquitin ligase Malin. Some substrates have already been provided by previous studies based on protein-protein interaction techniques and have been associated with some alterations that mark the disease. In this work, we have used an unbiased alternative approach based on the activity of Malin as an E3-ubiquitin ligase. We report the discovery of novel bonafide substrates of Malin and have characterized one of them more deeply, namely PIP3-dependent Rac exchanger 1 (P-Rex1). The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origin of the accumulation of the polyglucosans present in the disease., This work has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie SklodowskaCurie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), and a grant from la Fundacio ´ La Marato ´ TV3 (202032), to PS; and a grant from the Spanish Ministry of Science and Innovation PID2020- 112972RB-I00 to PS and MGG., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production

  • Mukhopadhyay, Rishov
  • Draganov, Simeon D
  • Oosenbrug, Timo
  • Akkermans, Jimmy J L L
  • Kikkert, Marjolein
  • Knobeloch, Klaus-Peter
  • Fritz, Günter
  • Guzmán, María
  • Zúñiga Lucas, Sonia
  • Kim, Robbert Q
  • van der Veen, Annemarthe G
  • Kessler, Benedikt M
  • Pinto-Fernández, Adán
  • Geurink, Paul P
  • Sapmaz, Aysegul
The type I Interferon (IFN-I)-induced ubiquitin-like modifier Interferon-Stimulated Gene 15 (ISG15) plays a crucial role in the innate immune response against viral infections. ISG15 is conjugated to target proteins by an enzymatic cascade, called ISGylation. While ubiquitin-specific protease 18 (USP18) serves as the major deISGylase counteracting ISG15 conjugation, ISG15 cross-reactive deubiquitylating enzymes (DUBs) have also been reported. Here, we identify USP24 as an ISG15 cross-reactive DUB through activity-based protein profiling. USP24 processes pro-ISG15 and ISG15-linked substrates in vitro, and its depletion increases ISG15 conjugates following interferon stimulation in cells without altering canonical IFN-I signaling. USP24 knockout cells show increased IFN-β and ISG expression upon activation of cytosolic RNA sensing via viral mimicry. Proteomic analysis identifies RNA helicase Moloney leukemia virus 10 (MOV10) as a specific target of USP24 for deISGylation. Our data revealed that ISGylation of MOV10 promotes MOV10 interaction with IFIT3 and enhances IFN-β production/secretion in response to viral stimuli. This process is negatively regulated by USP24, which directly deISGylates MOV10. Our data highlight USP24's role in modulating ISGylation and IFN-I production, suggesting USP24 as a potential therapeutic agent for infectious and inflammatory diseases., This work was supported by the TRIM-NET project, which received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813599. A.S was supported by ICI00026 from the NWO Gravity Program. S.D., A.P.F., and B.M.K. were supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China [grant number: 2018-I2M-2-002] and by Pfizer. Work in the A.P.F. lab was funded by Ono Pharma UK Ltd. S.Z. was supported by the Government of Spain (PID2022-140328OB-I00, MCIN/AEI/10.13039/501100011033/FEDER, UE). M.G. received a contract from Comunidad de Madrid (PIPF-2022/SAL-GL-24549). K.P.K. received funding from the German Research Foundation (DFG), Project ID DFG 423813989/GRK2606, and under Germany’s Excellence Strategy (CIBSS–EXC-2189–Project ID 390939984). T.O. and A.G.V.D.V. were supported by a research grant from the Institute for Chemical Immunology (ICI-00203 and ICI-00046), which is funded by a Gravitation project (024.002.009) from the Dutch Research Council (NWO), a VIDI research grant (09150171910070), and an Aspasia award (015.015.046) from the NWO, and the LUMC., Peer reviewed
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

P-Rex1 is a novel substrate of the E3 ubiquitin ligase Malin associated with Lafora disease

  • Kumarasinghe, Lorena
  • García Gimeno, María Adelaida
  • Ramírez Sánchez, Juan Manuel
  • Mayor Martínez, Ugo
  • Zugaza Gurruchaga, José Luis
  • Sanz, Pascual
Laforin and Malin are two proteins that are encoded by the genes EPM2A and EPM2B, respectively. Laforin is a glucan phosphatase and Malin is an E3-ubiquitin ligase, and these two proteins function as a complex. Mutations occurring at the level of one of the two genes lead to the accumulation of an aberrant form of glycogen meant to cluster in polyglucosans that go under the name of Lafora bodies. Individuals affected by the appearance of these polyglucosans, especially at the cerebral level, experience progressive neurodegeneration and several episodes of epilepsy leading to the manifestation of a fatal form of a rare disease called Lafora disease (LD), for which, to date, no treatment is available. Despite the different dysfunctions described for this disease, many molecular aspects still demand elucidation. An effective way to unknot some of the nodes that prevent the achievement of better knowledge of LD is to focus on the substrates that are ubiquitinated by the E3-ubiquitin ligase Malin. Some substrates have already been provided by previous studies based on protein-protein interaction techniques and have been associated with some alterations that mark the disease. In this work, we have used an unbiased alternative approach based on the activity of Malin as an E3-ubiquitin ligase. We report the discovery of novel bonafide substrates of Malin and have characterized one of them more deeply, namely PIP3-dependent Rac exchanger 1 (P-Rex1). The analysis conducted upon this substrate sets the genesis of the delineation of a molecular pathway that leads to altered glucose uptake, which could be one of the origin of the accumulation of the polyglucosans present in the disease., We want to thank Dr. Atanasio Pandiella (CIC-Salamanca), Dr. Manuel Rodríguez (Proteomics Unit. CIC-bioGUNE. Bizkaia. Spain), and Dr. Ch. Blattner (Institute of Toxicology and Genetics. Karlsruhe Institute of Technology. Karlsruhe. Germany) for plasmids. We also thank the support provided by SGIker Proteomics service (UPV/EHU - ERDF. EU). This work has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement 813599 (TRIM-NET). We also want to acknowledge the support of the grant from the National Institutes of Health P01 NS097197, which established the Lafora Epilepsy Cure Initiative (LECI), and a grant from la Fundació La Marató TV3 (202032), to PS; and a grant from the Spanish Ministry of Science and Innovation PID2020-112972RB-I00 to PS and MGG.